Vitamin D was used to treat tuberculosis in the pre-antibiotic era, but studies to evaluate the effect of vitamin D supplementation on antimycobacterial immunity have not previously been performed. We report that a single oral dose of vitamin D enhanced TB contacts' immunity to mycobacteria in a randomized controlled trial. 
Measurements and Main Results
The primary outcome measure was assessed with a functional whole blood assay (BCGlux assay) that measures the ability of whole blood to restrict luminescence, and thus growth, of recombinant reporter mycobacteria in vitro; the read-out is expressed as a luminescence ratio (luminescence post-infection/baseline luminescence). Interferongamma responses to the M. tuberculosis antigens early secretory antigenic target-6 and culture filtrate protein 10 were determined with a second whole blood assay.
Introduction
Tuberculosis (TB) is a global emergency: in 2004 there were an estimated 8.9 million new cases and 1.7 million deaths due to the disease (1) . One third of the global population has latent TB infection (LTBI) (2) , providing a reservoir for future reactivation disease well into the present century. An understanding of the factors causing reactivation is therefore of considerable public health significance.
Clinical studies suggest that vitamin D enhances antimycobacterial immunity, and that deficiency is associated with susceptibility to active disease. High doses of vitamin D were widely used to treat active TB in the pre-antibiotic era (3); more recently, case control studies have demonstrated that vegetarian diet (low in vitamin D) is an independent risk factor for active TB in south Asians (4) and that TB patients of Gujarati Hindu ethnic origin have significantly higher rates of vitamin D deficiency than ethnically matched tuberculin positive TB contacts (5).
Vitamin D is synthesized in the skin during exposure to ultraviolet light and is also available in the diet, principally from oily fish. It is readily metabolized in the liver to form 25-hydroxy-vitamin D (25(OH)D), the accepted measure of vitamin D status (6 has also been shown to support messenger RNA induction of the antimicrobial peptide cathelicidin LL-37 which possesses antituberculous activity (14) .
Randomized controlled trials evaluating the effect of vitamin D supplementation on antimycobacterial host response have yet to be performed. Placebo-controlled prospective studies in tuberculin positive individuals with the development of active TB as primary outcome measure would require very large sample sizes to detect clinically significant effects. We therefore adopted an alternative approach, conducting a double-blind randomized controlled trial of vitamin D supplementation in a large cohort of TB contacts in London, UK, using a surrogate primary outcome measure: the BCG-lux assay (15) . In this assay, whole blood is cultured with a recombinant M. bovis Bacille Calmette Guérin (BCG) expressing luciferase, an enzyme that catalyzes the conversion of aldehyde substrate to produce light detectable in a luminometer. Because this reaction is ATPdependent, light production relates to bacillary metabolic activity and colony forming units (CFU) (16) . The ability of whole blood to suppress BCG-lux bioluminescence is determined at both 24 and 96 hours post-infection, in order to assay innate and acquired components of host response, respectively. This model has yielded intuitive correlates of protection in several previous studies (15, 17, 18) .
We combined BCG-lux analysis with a whole blood Interferon-gamma (IFN-) release assay (IFNGRA) that quantifies IFN-response to the M. tuberculosis antigens early secretory antigenic target-6 (ESAT-6) and culture filtrate protein 10 (CFP-10) (19) .
Antigen-stimulated IFN-production is an often-utilized correlate of protective immunity to M. tuberculosis infection (20) , and this assay therefore served as a second indicator of the acquired host response. We also determined 25(OH)D concentrations in serum of all subjects at baseline and follow-up, and in BCG-lux assay supernatants of a randomly selected subgroup of participants.
Some of the results of this study have been previously reported in the form of an abstract (21) .
Methods

Participants
Study participants were recruited from TB contact clinics at Newham and Northwick Park Hospitals, London, UK. All people over 17 years of age who had been exposed to a patient with active TB were assessed. Individuals were excluded if they had symptoms, clinical signs or radiographic evidence of active TB; HIV infection, renal failure, sarcoidosis or hyperparathyroidism; if they were taking corticosteroids, thiazide diuretics or supplementary vitamin D (either alone or as part of a multivitamin preparation); or if they were breastfeeding or pregnant. Socio-demographic and dietary details were recorded on case report forms. Participants self-classified ethnicity into one of the following five categories (22) : black African, south Asian, white, mixed or other. A blood sample was drawn for baseline assays, a tuberculin skin test was performed according to national guidelines (23) and a urine sample was collected from women of childbearing age for pregnancy test. TB contacts were reviewed at one week, and the grade of the tuberculin reaction was recorded. The study nurse then allocated a study ID number to eligible participants, and administered study medication from a container labeled with that number.
These containers had previously been filled with either a single oral dose of 2.5 mg ergocalciferol or lactose placebo of identical appearance, according to a computergenerated sequence of random numbers in blocks of ten. Participants were reviewed at 6 weeks post-randomization, when a second blood sample was drawn for follow-up assays.
The study research nurse and all participants and individuals performing laboratory assays were blinded to allocation. The study was approved by the Research Ethics Committees of North East London and Harrow (REC refs. P/02/146 and EC 2759 respectively), and written informed consent to participate was obtained from all participants.
Whole blood assays
The primary outcome measure was BCG-lux assay luminescence ratio. This assay has been described elsewhere (15) . Briefly, M. bovis-BCG transformed with a replicating vector containing the luciferase (lux) gene of Vibrio harveyi was prepared as previously described (16) . Frozen aliquots of BCG-lux bacilli were grown to mid-log phase in Middlebrook 7H9 The IFNGRA used in this study has also been described elsewhere (19) . Triplicate samples of venous blood diluted 1:10 with RPMI-1640 (Sigma, Poole, UK) were cultured with 2.5 µg/ml recombinant ESAT-6 (24), 5 µg/ml CFP-10 (Lionex, Braunschweig, Germany) or no stimulus at 37ºC in 5% CO 2 . Supernatants were aspirated at 96 hours for determination of IFN-concentration by ELISA using an antibody pair from BD (assay sensitivity <10 pg/ml).
Determination of 25(OH)D concentration
Concentrations of 25(OH)D 2 and 25(OH)D 3 were determined by isotope-dilution liquid chromatography-tandem mass spectrometry (25) 
Results
We assessed 364 TB contacts for eligibility between December 16 Baseline characteristics of these 131 participants are compared in Table 1 nmol/l; P<0.0001; Figure 3C ).
Discussion
We have shown that a single oral dose of 2. A large proportion of TB contacts assessed for eligibility declined randomization ( Figure   1) ; however, the fact that this group did not differ significantly from participants in terms of median age, sex ratio or ethnic composition suggests that the external validity of this study is unlikely to have been severely compromised by its low recruitment rate. The significant numbers of participants who were lost to follow-up or excluded from the analysis also represent a weakness of the study, primarily by increasing the potential for type II error.
The very high rates of profound vitamin D deficiency that we report in this group of otherwise healthy adults are higher than those documented in the institutionalized elderly (29) and are a cause for grave public health concern, given emerging evidence implicating • taking thiazide diuretics (6) • at risk of pregnancy (6) • breastfeeding (2) • renal failure (2) • pregnant (1) • HIV-infected (1)
Excluded after baseline blood test prior to randomization: n=10 -withdrew consent ( 
